Beta Drugs Limited

Ask AI

Key metrics

Price as of 2026-07-17

Stock price
₹2229.10
Market cap
2,260 Cr
Stock P/E
54.5
P/B
9.23

Sign in for full ratios and TTM. Learn about these metrics →

Share price

NSE closing price from historical market data.

Loading price history…

Statement tables · Consolidated

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Only consolidated filings are available for this company — standalone cannot be selected.

Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricDec 2025Mar 2026
Sales87 Cr94 Cr
Operating expenses (approx.)68 Cr73 Cr
EBITDA19 Cr21 Cr
OPM %22.1%21.9%
Other income2 Cr3 Cr
Interest4 Cr4 Cr
Depreciation4 Cr5 Cr
Profit before tax10 Cr12 Cr
Tax %18.7%23.5%
Net profit9 Cr9 Cr
EPS (₹)₹8.40₹8.93

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricMar 2025Mar 2026TTM
Sales362 Cr385 CrSign in for TTM
Operating expenses (approx.)286 Cr298 CrSign in for TTM
EBITDA76 Cr87 CrSign in for TTM
OPM %21.1%22.6%Sign in for TTM
Other income6 Cr11 CrSign in for TTM
Interest7 Cr15 CrSign in for TTM
Depreciation13 Cr17 CrSign in for TTM
Profit before tax57 Cr54 CrSign in for TTM
Tax %25.5%23.7%Sign in for TTM
Net profit42 Cr41 CrSign in for TTM
EPS (₹)₹42.02₹40.92Sign in for TTM
Dividend payout %0.0%0.0%Sign in for TTM
Sign in for TTM

Trailing twelve months totals and margin rows

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricMar 2025Mar 2026
Equity capital10 Cr10 Cr
Reserves187 Cr235 Cr
Borrowings14 Cr
Other liabilities239 Cr237 Cr
Total liabilities436 Cr496 Cr
Fixed assets (net)80 Cr115 Cr
CWIP0.0000 Cr
Investments0.0000 Cr0.0000 Cr
Other assets331 Cr335 Cr
Total assets436 Cr496 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricMar 2025Mar 2026
Cash from operating activity32 Cr37 Cr
Cash from investing-36 Cr-51 Cr
Cash from financing118 Cr-8 Cr
Net cash flow114 Cr-22 Cr
Free cash flow (OCF − Capex)-0.91 Cr-13 Cr

Ratios

Ratios as reported or derived per annual period.

MetricMar 2025Mar 2026
ROCE %32.5%26.9%
ROE %21.5%16.9%
Debtor days103
Inventory days124156
Days payable148
Cash conversion cycle79156
Debt / equity0.00710.06
Current ratio3.223.10
Net debt / EBITDA-0.0029-1.27